Iran has kicked off the final stage of the clinical trial of its domestic Covid-19 vaccine as two volunteers were inoculated, semi-official Mehr news agency reported.
"Phase 1 was successfully completed with 56 volunteers, and today phases 2 and 3 of the clinical trial began," director of the clinical trial centre at Tehran University of Medical Sciences (TUMS) Hamed Hosseini said on Monday.
The receivers of the COV-Iran Barekat vaccine were two lecturers at TUMS.
Iran has so far reported a total of 1,754,933 coronavirus cases and 61,330 deaths.
At least 1,499,301 Covid-19 patients have recovered, but 3,839 others remain in critical condition, according to official figures.
--IANS
ksk/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU